Astellas Pharma Inc. (ALPMY) on Decifer

Decifer ranks ALPMY number 156 of 265 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 13% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 19% a year and profits grew 509% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• 19 percent revenue growth and 509 percent profit growth are strong but 10 momentum with no growth role leaves the thesis empty.

The current read

The evidence on ALPMY lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Read the full ALPMY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.